These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 6543135)
41. Serum concentrations of isosorbide dinitrate produced by a sustained-release capsule. Halkin H; Almog S; Friedman E Isr J Med Sci; 1979 May; 15(5):448-50. PubMed ID: 447513 [TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetics of sustained-release capsule of 5-isosorbide mononitrate in 20 healthy Chinese young men. Luo WX; Zhang YD; Shen JP; Ding Y; Huang DK; Luo JP; Qiu J; Jiang ZH; Peng JH; Sheng LS Zhongguo Yao Li Xue Bao; 1999 Oct; 20(10):951-6. PubMed ID: 11270999 [TBL] [Abstract][Full Text] [Related]
43. [Pharmacodynamic effects of the sustained-release tablet of isosorbide dinitrate and its bioavailability in conscious dogs (author's transl)]. Kogi K; Chida S; Kimura T; Saito T Nihon Yakurigaku Zasshi; 1980 Mar; 76(2):99-107. PubMed ID: 7399370 [TBL] [Abstract][Full Text] [Related]
44. [Assay of plasma isosorbide dinitrate and its metabolites after oral administration of immediate and delayed-action forms]. Audry E; Dallet P; Dubost JP; Langlois MH; Ernouf D; Narcisse G Ann Pharm Fr; 1989; 47(4):235-41. PubMed ID: 2637644 [TBL] [Abstract][Full Text] [Related]
45. A pharmacokinetic model for isosorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate. Smith D; Aldrich W; Dey M; Enever R; Warner R; Weierstall R Drug Metab Dispos; 1990; 18(4):429-34. PubMed ID: 1976063 [TBL] [Abstract][Full Text] [Related]
46. [The evaluation of the bioavailability of isosorbide 5-mononitrate]. Dyderski S; Szkutnik D; Drobnik L; Szymańska-Shawkat E Pol Merkur Lekarski; 1999 Aug; 7(38):64-6. PubMed ID: 10522420 [TBL] [Abstract][Full Text] [Related]
47. A combined single and multiple dose pharmacokinetic study of oral isosorbide-5-mononitrate in healthy volunteers. Storm G; Oosterhuis B; Bron J; Wittebrood AJ; De Jong AP; Jonkman JH Biopharm Drug Dispos; 1991 Dec; 12(9):661-72. PubMed ID: 1790311 [TBL] [Abstract][Full Text] [Related]
48. [Pharmacokinetics of low-dose isosorbide dinitrate and metabolites after buccal or oral administration]. Keller-Stanislawski B; Marschner JP; Rietbrock N Arzneimittelforschung; 1992 Jan; 42(1):17-20. PubMed ID: 1586374 [TBL] [Abstract][Full Text] [Related]
49. Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man. Laufen H; Aumann M; Leitold M Arzneimittelforschung; 1983; 33(7):980-4. PubMed ID: 6684933 [TBL] [Abstract][Full Text] [Related]
50. In vitro and in vivo evaluation of novel osmotic pump tablets of isosorbide-5-mononitrate containing polyvinyl pyrrolidone (PVP) for controlled release. Li X; Jiang Q; Du L; Wang C; Chi Q Pharmazie; 2012 Aug; 67(8):695-700. PubMed ID: 22957434 [TBL] [Abstract][Full Text] [Related]
51. [Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system]. Menke G; Schnellhammer R; Rietbrock N Arzneimittelforschung; 1987 Nov; 37(11):1301-3. PubMed ID: 3440041 [TBL] [Abstract][Full Text] [Related]
52. [Pharmacokinetics and bioavailability of a new slow-release isosorbide-5-mononitrate system]. Gandini R; Cunietti E; Assereto R; Castoldi D; Tofanetti O; Baggio E Cardiologia; 1987 Nov; 32(11):1287-91. PubMed ID: 3447701 [No Abstract] [Full Text] [Related]
53. [Efficacy and duration of action of isosorbide-5-mononitrate in the treatment of stable angina of effort. Comparison with sustained-release isosorbide dinitrate]. Lagioia R; Scrutinio D; Mangini SG; De Toma L; Accettura D; De Nicolò M; Saliani P; Preziusi N; Antuofermo F; Rizzon P G Ital Cardiol; 1985 Mar; 15(3):299-306. PubMed ID: 4018470 [TBL] [Abstract][Full Text] [Related]
54. [Study of the bioequivalence of a new isosorbide dinitrate tablet formulation compared with the standard preparation]. Metzner JE; Buchberger D; Häring N; Läuter J Arzneimittelforschung; 1997 Jun; 47(6):719-26. PubMed ID: 9281301 [TBL] [Abstract][Full Text] [Related]
55. Effect of food on the oral bioavailability of isosorbide-5-mononitrate administered as an extended-release tablet. Kosoglou T; Kazierad DJ; Schentag JJ; Patrick JE; Heimark L; Radwanski E; Christopher D; Flannery BE; Affrime MB J Clin Pharmacol; 1995 Feb; 35(2):151-8. PubMed ID: 7751425 [TBL] [Abstract][Full Text] [Related]
56. Evaluation of novel immediate-/controlled-release tablets of isosorbide-5-mononitrate (5-ISMN): in vitro-in vivo correlation. Li X; Jiang Q; Du L; Li Y; Li M Pharmazie; 2014 Feb; 69(2):109-16. PubMed ID: 24640599 [TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate. Schaumann W Int J Clin Pharmacol Ther Toxicol; 1989 Sep; 27(9):445-53. PubMed ID: 2681004 [TBL] [Abstract][Full Text] [Related]
58. First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man. Abshagen U; Spörl-Radun S Eur J Clin Pharmacol; 1981; 19(6):423-9. PubMed ID: 7250175 [TBL] [Abstract][Full Text] [Related]
59. Utilization of diethyl-beta-cyclodextrin as a sustained-release carrier for isosorbide dinitrate. Hirayama F; Hirashima N; Abe K; Uekama K; Ijitsu T; Ueno M J Pharm Sci; 1988 Mar; 77(3):233-6. PubMed ID: 3373427 [TBL] [Abstract][Full Text] [Related]
60. Evaluation of bioavailability and pharmacokinetics of two isosorbide-5-mononitrate preparations in healthy volunteers. Hutt V; Theodor R; Pabst G; Bonn R; Fritschi E; Jaeger H J Clin Pharmacol; 1992 Jun; 32(6):553-7. PubMed ID: 1634643 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]